Intelligence Profile
Research Papers
Key Research Papers and Clinical Trials
Recent research on adipose-derived stem cell therapy spans multiple therapeutic applications, though most evidence comes from preclinical studies with limited clinical trial data available.
Preclinical Research
Several 2026 studies have explored the regenerative potential of adipose-derived stem cells (ADSCs) across different applications:
Tissue Engineering and Wound Healing: Research has examined ADSCs for cartilage regeneration using specialized scaffolds, comparing their chondrogenic potential to dental pulp stem cells. Another study investigated ADSCs in chronic wound healing, while additional work explored how iron-quercetin nanocomplex preconditioning can reprogram ADSC secretomes to enhance wound repair through angiogenic and immunoregulatory mechanisms.
Organ Protection: A study focused on ADSCs for acute kidney injury caused by ischemia-reperfusion, specifically examining their effects on toll-like receptor 4 activity and cellular stress responses. The research suggests potential protective mechanisms, though clinical translation remains to be demonstrated.
Specialized Applications: Recent work has evaluated how different wavelengths of photobiomodulation affect ADSC differentiation into tendon-like cells, providing insights into optimizing cell-based therapies for tendon repair.
Clinical Trial Landscape
The clinical evidence for ADSC therapy remains limited, with most trials in early phases:
Completed Studies: Only two trials have reported completion - a Phase 1 study of allogeneic ADSCs for Crohn's fistula (NCT01440699) and a Phase 1/2 trial for cerebellar ataxia treatment (NCT01649687). However, detailed results from these completed studies are not provided in the available evidence.
Ongoing/Unknown Status Trials: Several trials are investigating diverse applications including female sexual dysfunction (Phase 2, NCT05329662), intravenous ADSC infusion (Phase 1, NCT04744051), and recto-vaginal fistula treatment using stromal vascular fraction (Phase 1/2, NCT01548092).
Evidence Limitations
The current evidence base shows significant gaps. While preclinical research demonstrates promising mechanisms and potential applications, robust clinical data demonstrating safety and efficacy in humans remains sparse. Most clinical trials are in early phases or have unknown status, limiting conclusions about therapeutic effectiveness.
Note: This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for treatment decisions.